Ce Shi

1.6k total citations · 1 hit paper
51 papers, 794 citations indexed

About

Ce Shi is a scholar working on Molecular Biology, Hematology and Immunology. According to data from OpenAlex, Ce Shi has authored 51 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 15 papers in Hematology and 10 papers in Immunology. Recurrent topics in Ce Shi's work include Acute Myeloid Leukemia Research (6 papers), Acute Lymphoblastic Leukemia research (6 papers) and Cell death mechanisms and regulation (5 papers). Ce Shi is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Acute Lymphoblastic Leukemia research (6 papers) and Cell death mechanisms and regulation (5 papers). Ce Shi collaborates with scholars based in China, United States and Japan. Ce Shi's co-authors include E Haber, John Newell, Donald L. Fletcher, W S Lee, Qi He, Dong Zhang, Mary E. Russell, Cesario Bianchi, Peter Carmeliet and Edward F. Plow and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Blood.

In The Last Decade

Ce Shi

46 papers receiving 786 citations

Hit Papers

Fecal microbiota transplantation from young mice rejuvena... 2023 2026 2024 2025 2023 25 50 75

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ce Shi China 14 361 197 160 146 131 51 794
Rafia S. Al‐Lamki United Kingdom 17 410 1.1× 201 1.0× 306 1.9× 127 0.9× 34 0.3× 22 1.1k
Elsie Oppermann Germany 19 304 0.8× 146 0.7× 184 1.1× 115 0.8× 46 0.4× 58 997
Galit Shahaf Israel 16 304 0.8× 131 0.7× 156 1.0× 244 1.7× 95 0.7× 23 801
Xiaohu Fan Canada 13 223 0.6× 166 0.8× 82 0.5× 161 1.1× 42 0.3× 18 596
Christopher Geehan United States 11 335 0.9× 168 0.9× 424 2.6× 90 0.6× 53 0.4× 12 924
Lawrence H. Chow Canada 12 388 1.1× 216 1.1× 146 0.9× 176 1.2× 45 0.3× 16 892
Günter Weigel Austria 13 302 0.8× 156 0.8× 76 0.5× 44 0.3× 56 0.4× 23 698
Bryce G. Johnson United States 12 579 1.6× 114 0.6× 144 0.9× 204 1.4× 41 0.3× 15 1.1k
Heiko Methe Germany 16 306 0.8× 219 1.1× 471 2.9× 102 0.7× 30 0.2× 34 969
Toshihiro Shimizu Japan 15 402 1.1× 123 0.6× 78 0.5× 110 0.8× 15 0.1× 64 910

Countries citing papers authored by Ce Shi

Since Specialization
Citations

This map shows the geographic impact of Ce Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ce Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ce Shi more than expected).

Fields of papers citing papers by Ce Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ce Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ce Shi. The network helps show where Ce Shi may publish in the future.

Co-authorship network of co-authors of Ce Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Ce Shi. A scholar is included among the top collaborators of Ce Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ce Shi. Ce Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shi, Ce, Xiangjun Zeng, Yi Luo, et al.. (2025). Machine learning-based prediction of G-CSF-induced hematopoietic stem cell mobilization outcomes in healthy volunteers. Bone Marrow Transplantation. 60(10). 1316–1324.
3.
Shi, Ce, et al.. (2024). m6A methylation regulators and ncRNAs in osteosarcoma: Potential therapeutic strategies. Progress in Biophysics and Molecular Biology. 194. 34–42. 2 indexed citations
4.
Sun, Xu, et al.. (2024). Targeting the mitochondrial protein YME1L to inhibit osteosarcoma cell growth in vitro and in vivo. Cell Death and Disease. 15(5). 346–346. 4 indexed citations
5.
Zeng, Xiangjun, Xiaoqing Li, Xia Li, et al.. (2023). Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation. Blood. 141(14). 1691–1707. 96 indexed citations breakdown →
6.
Li, Dinuo, Yu Wang, Ce Shi, et al.. (2023). Targeting GPC3 high cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer. Annals of Medicine. 55(1). 2189295–2189295. 20 indexed citations
7.
Shan, Huajian, Ce Shi, Min‐Bin Chen, et al.. (2022). Identification of Gαi3 as a promising target for osteosarcoma treatment. International Journal of Biological Sciences. 18(4). 1508–1520. 25 indexed citations
8.
Tian, Yuan, Ce Shi, Yi Wang, et al.. (2021). Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T‐cell acute lymphoblastic leukemia. Hematological Oncology. 40(2). 249–257. 6 indexed citations
9.
Liu, Xiaohan, Siwen Li, Yuan Meng, et al.. (2021). Osteoclast differentiation and formation induced by titanium implantation through complement C3a. Materials Science and Engineering C. 122. 111932–111932. 12 indexed citations
10.
Shi, Ce, Zhenkun Wang, Wei Jia, et al.. (2020). Alantolactone inhibits cell autophagy and promotes apoptosis via AP2M1 in acute lymphoblastic leukemia. Cancer Cell International. 20(1). 442–442. 15 indexed citations
11.
Shi, Ce, et al.. (2020). Pseudogene MSTO2P enhances hypoxia-induced osteosarcoma malignancy by upregulating PD-L1. Biochemical and Biophysical Research Communications. 530(4). 673–679. 8 indexed citations
12.
Zheng, Yufan, Jinyu Bai, Ce Shi, et al.. (2020). Hepatocyte growth factor overexpression promotes osteoclastogenesis and exacerbates bone loss in CIA mice. Journal of Orthopaedic Translation. 27. 9–16. 15 indexed citations
14.
Wang, Yu, Yuqiang Li, Bin Wu, Ce Shi, & Chen Li. (2017). MicroRNA-661 promotes non-small cell lung cancer progression by directly targeting RUNX3. Molecular Medicine Reports. 16(2). 2113–2120. 26 indexed citations
15.
Wu, Xiaoyan, Zhenhua Hu, Sara Nizzero, et al.. (2017). Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. Journal of Controlled Release. 268. 92–101. 32 indexed citations
16.
Zhāng, Qí, Lina Han, Ce Shi, et al.. (2016). Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML. Blood. 128(22). 101–101. 5 indexed citations
17.
Zhong, Yanwei, Hongfei Zhang, Yongli Li, et al.. (2016). IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C. International Journal of Biological Sciences. 12(11). 1357–1362. 3 indexed citations
18.
Cao, Fenglin, Hui Zhao, Xiuhua Liu, et al.. (2013). Arsenic Trioxide Inhibits the Hedgehog Pathway Which Is Aberrantly Activated in Acute Promyelocytic Leukemia. Acta Haematologica. 130(4). 260–267. 32 indexed citations
19.
Zhang, Zhuo, Yan Chen, Qian Zhou, et al.. (2013). Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. Leukemia & lymphoma. 54(9). 2041–2046. 6 indexed citations
20.
Moons, Lieve, Ce Shi, Victoria A. Ploplis, et al.. (1998). Reduced transplant arteriosclerosis in plasminogen-deficient mice.. Journal of Clinical Investigation. 102(10). 1788–1797. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026